title: Systems approach for the selection of micro-RNAs as therapeutic biomarkers of anti-EGFR monoclonal antibody treatment in colorectal cancer.
abstract: miRNA plays an important role in tumourgenesis by regulating expression of oncogenes and tumour suppressors. Thus affects cell proliferation and differentiation, apoptosis, invasion and angiogenesis. miRNAs are potential biomarkers for diagnosis, prognosis and therapies of different forms of cancer. However, relationship between response of cancer patients towards targeted therapy and the resulting modifications of the miRNA transcriptome in the context of pathway regulation is poorly understood. With ever-increasing pathways and miRNA-mRNA interaction databases, freely available mRNA and miRNA expression data in multiple cancer therapy have produced an unprecedented opportunity to decipher the role of miRNAs in early prediction of therapeutic efficacy in diseases. Efficient translation of -omics data and accumulated knowledge to clinical decision-making are of paramount scientific and public health interest. Well-structured translational algorithms are needed to bridge the gap from databases to decisions. Herein, we present a novel SMARTmiR algorithm to prospectively predict the role of miRNA as therapeutic biomarker for an anti-EGFR monoclonal antibody i.e. cetuximab treatment in colorectal cancer.
authors.affiliation: 1] Fraunhofer Institute SCAI, Schloss Birlinghoven, 53754 Sankt Augustin, Germany [2] Bonn-Aachen International Center for Information Technology (B-IT), Department of Applied Life Science Informatics, 53113 Bonn, Germany.
authors.forename: Avisek
authors.initials: A
authors.lastname: Deyati
authors.affiliation: 1] Fraunhofer Institute SCAI, Schloss Birlinghoven, 53754 Sankt Augustin, Germany [2] Bonn-Aachen International Center for Information Technology (B-IT), Department of Applied Life Science Informatics, 53113 Bonn, Germany.
authors.forename: Shweta
authors.initials: S
authors.lastname: Bagewadi
authors.affiliation: 1] Fraunhofer Institute SCAI, Schloss Birlinghoven, 53754 Sankt Augustin, Germany [2] Bonn-Aachen International Center for Information Technology (B-IT), Department of Applied Life Science Informatics, 53113 Bonn, Germany.
authors.forename: Philipp
authors.initials: P
authors.lastname: Senger
authors.affiliation: 1] Fraunhofer Institute SCAI, Schloss Birlinghoven, 53754 Sankt Augustin, Germany [2] Bonn-Aachen International Center for Information Technology (B-IT), Department of Applied Life Science Informatics, 53113 Bonn, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Hofmann-Apitius
authors.affiliation: Merck Serono, Frankfurter Strasse 250, 64293 Darmstadt, Germany.
authors.forename: Natalia
authors.initials: N
authors.lastname: Novac
mesh_terms: D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D002454:Cell Differentiation / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D000068818:Cetuximab / Q000627:therapeutic use / Q000633:toxicity; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D066246:ErbB Receptors; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D035683:MicroRNAs / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D035683:MicroRNAs; D066246:ErbB Receptors; D000068818:Cetuximab